NYSE$MOH
Molina Healthcare Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Molina Healthcare's financial performance improved with increased premium revenue and net income, driven by effective cost management and the impacts of the COVID-19 pandemic.
Molina Healthcare reported a strong second quarter with increased net income and premium revenue. The company's performance was positively impacted by reduced demand for medical services due to the COVID-19 pandemic, which was partially offset by COVID-related premium rate refunds and direct medical costs. The company introduced full year 2021 premium revenue guidance of approximately $21.5 billion, representing 20% growth over 2020.
- Premium revenue increased by 8.0% to $4.4 billion compared to the second quarter of 2019.
- Medical care ratio (MCR) improved to 82.3% compared to 85.6% in the second quarter of 2019.
- Net income rose to $276 million, compared to $196 million for the second quarter of 2019.
- The company estimates that COVID-19 increased second quarter after-tax income by approximately $65 million to $100 million.
Headline financials
Revenue & EPS history
Molina · Revenue · Quarterly
$4.62B
Revenue by segment
Molina · $8.04B total across 3 segments · Q2 2023
- Medicaid$6.49B+2.9%80.6%
- Medicare$1.04B+9.1%13.0%
- Marketplace$513M-5.2%6.4%
Forward guidance
The Company has increased its full year 2020 total revenue outlook to approximately $18.8 billion, from its previous estimate of $18.3 billion. The Company introduced full year 2021 premium revenue guidance of approximately $21.5 billion, or 20% growth over 2020.
Tailwinds
- Full year earnings guidance range remains at $11.20 to $11.70 per diluted share.
- Full year 2020 total revenue outlook increased to approximately $18.8 billion.
- Full year 2021 premium revenue guidance of approximately $21.5 billion, or 20% growth over 2020.
- Kentucky Medicaid managed care RFP was awarded to Molina.
- Acquisition of YourCare assets was completed.
Headwinds
- Environmental uncertainty is expected to exist through the end of the year.
- COVID-related premium rate refunds.
- Impact of lower pricing in the Marketplace program.
- Direct COVID-19 medical costs.
- Unspecified risks and uncertainties that could affect future developments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+0.2%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.9%
Avg return
30 days after
41%
27 / 66 earnings
Positive
+26.3%
Q1 2017
Best reaction
-25.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +21.2% | +20.3% | |
| Q4 2025 | -25.5% | -30.6% | -18.3% | |
| Q3 2025 | -17.3% | -16.5% | -27.5% | |
| Q2 2025 | +4.9% | +8.8% | +13.3% | |
| Q1 2025 | -5.5% | -3.7% | -8.1% | |
| Q4 2024 | -10.1% | -13.9% | +3.3% | |
| Q3 2024 | +14.0% | +11.0% | +2.4% | |
| Q2 2024 | +13.0% | +16.1% | +20.5% | |
| Q1 2024 | -3.0% | -5.3% | -8.6% | |
| Q4 2023 | +6.8% | +9.9% | +9.9% | |
| Q3 2023 | -0.7% | -1.7% | +10.1% | |
| Q2 2023 | -2.6% | -3.5% | +1.0% | |
| Q1 2023 | +6.3% | +9.4% | -2.2% | |
| Q4 2022 | -0.5% | -1.1% | -13.7% | |
| Q3 2022 | -3.9% | -2.0% | -10.7% | |
| Q2 2022 | +2.7% | +5.3% | +9.7% | |
| Q1 2022 | -1.9% | -4.7% | -5.1% | |
| Q4 2021 | -0.5% | -0.0% | +1.8% | |
| Q3 2021 | -0.8% | -0.5% | -2.4% | |
| Q2 2021 | -2.0% | +5.4% | +3.2% | |
| Q1 2021 | +1.2% | +2.2% | +0.2% | |
| Q4 2020 | +5.0% | +5.0% | +12.9% | |
| Q3 2020 | -8.2% | -2.5% | +1.5% | |
| Q2 2020 | -1.6% | -0.5% | -2.0% | |
| Q1 2020 | +5.2% | +9.9% | +12.8% | |
| Q4 2019 | +10.5% | +13.3% | +3.1% | |
| Q3 2019 | -0.3% | -4.4% | +11.0% | |
| Q2 2019 | -4.4% | -7.0% | -6.5% | |
| Q1 2019 | +0.9% | -0.2% | +2.0% | |
| Q4 2018 | -5.5% | -1.1% | +3.6% | |
| Q3 2018 | -0.8% | -0.9% | +11.1% | |
| Q2 2018 | +18.7% | +23.1% | +34.7% | |
| Q1 2018 | -2.9% | -1.2% | +3.4% | |
| Q4 2017 | -3.8% | -8.1% | -2.8% | |
| Q3 2017 | +16.1% | +13.7% | +14.6% | |
| Q2 2017 | -6.8% | -12.4% | -4.0% | |
| Q1 2017 | +26.3% | +30.8% | +31.3% | |
| Q4 2016 | -17.2% | +1.6% | -6.0% | |
| Q3 2016 | -5.9% | -7.0% | -9.3% | |
| Q2 2016 | +10.1% | +8.1% | +4.2% | |
| Q1 2016 | -20.6% | — | — | |
| Q4 2015 | -1.5% | — | — | |
| Q3 2015 | -8.6% | — | — | |
| Q2 2015 | +9.6% | — | — | |
| Q1 2015 | +11.6% | — | — | |
| Q4 2014 | +8.8% | — | — | |
| Q3 2014 | +4.6% | — | — | |
| Q2 2014 | -6.5% | — | — | |
| Q1 2014 | +4.5% | — | — | |
| Q4 2013 | -6.4% | — | — | |
| Q3 2013 | -7.5% | — | — | |
| Q2 2013 | -1.4% | — | — | |
| Q1 2013 | +1.6% | — | — | |
| Q4 2012 | +10.0% | — | — | |
| Q3 2012 | +14.3% | — | — | |
| Q2 2012 | -1.7% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q1 2012 | +0.2% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q1 2010 | -0.2% | — | — | |
| Q4 2009 | -0.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q3 2011 | +1.2% | — | — | |
| Q2 2011 | -2.7% | — | — | |
| Q4 2010 | -2.7% | — | — | |
| Q2 2010 | -2.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro